Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs

Journal of Inherited Metabolic Disease

Volumn 32, Issue SUPPL. 1, 2009, Pages

  Passage, M B ^a   Krieger, A W ^a   Peinovich, M C ^a   Lester, T ^b   Le, S Q ^a   Dickson, P I ^a   Kakkis, E D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; LEVO IDURONIDASE; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BLOOD; COMPARATIVE STUDY; DISEASE MODEL; DOG; ENZYME REPLACEMENT; EQUIPMENT; EVALUATION; HUMAN; HURLER SYNDROME; INFUSION PUMP; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; ENZYME REPLACEMENT THERAPY; GLYCOSAMINOGLYCANS; HUMANS; IDURONIDASE; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; MUCOPOLYSACCHARIDOSIS I; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84881013011     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1198-5     Document Type: Article

References (12)

1. Barton NW, Brady RO, Dambrosia JM, et al (1991) Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464-1470.
2. Dickson P, Peinovich M, McEntee M, et al (2008) Immune tolerance improves the efficacy of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. J Clin Invest 118: 2868-2876.
3. Eng CM, Guffon N, Wilcox WR, et al (2001) Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry-s disease. N Engl J Med 345: 9-16. doi:10.1056/NEJM200107053450102 (Pubitemid 32634266)
4. Giugliani R, Rojas VM, Martins AM, et al (2009) A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab 96: 13-19. doi:10.1016/j.ymgme.2008.10.009
5. Harmatz P, Kramer WG, Hopwood JJ, et al (2005) Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr Suppl 94: 61-68. doi:10.1080/08035320510028139
6. Jakisch BI, Wagner VM, Heidtmann B, et al (2008) Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily infusions (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabet Med 25: 80-85.
7. Kakkis ED, Matynia A, Jonas AJ, et al (1994) Overexpression of the human lysosomal enzyme a-L-iduronidase in Chinese hamster ovary cells. Protein Expr Purif 5 : 225-232. doi:10.1006/prep.1994.1035 (Pubitemid 2097008)
8. Kakkis ED, McEntee MF, Schmidtchen A, et al (1996) Longterm and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 58: 156-167. doi:10.1006/bmme.1996.0044 (Pubitemid 26262358)
9. Kakkis ED, Muenzer J, Tiller GE, et al (2001) Enzymer-eplacement therapy in mucopolysaccharisosis I. N Engl J Med 344: 182-188. doi:10.1056/ NEJM200101183440304
10. Kishnani PS, Nicolino M, Voit T, et al (2006) Chinese hamster ovary cell-derived recombinant human acid a-glucosidase in infantile-onset Pompe disease. J Pediatr 149 : 89-97. doi:10.1016/j.jpeds.2006.02.035 (Pubitemid 44081924)
11. Muenzer J, Wraith JE, Beck M, et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8: 465-473. doi:10.1097/01.gim.0000232477.37660.fb
12. Wraith JE, Beck M, Lane R, et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human a-Liduronidase (laronidase). Pediatrics 120: e37-e46. doi:10.1542/peds.2006-2156 (Pubitemid 47036214)